News Drug Development

Pfizer Inc. Reports Promising Phase II Data On Lung Cancer Drug, PF-00299804

October 12, 2010 |

1 min read

Pharma Times -- Pfizer’s investigational agent PF-00299804 has shown an ability to prevent disease progression when given as a first-line treatment in patients with advanced non-small cell lung cancer.

Clinical research Phase II

Pfizer

MORE ON THIS TOPIC

Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.

Duchenne muscular dystrophy

Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment

January 26, 2026

·

2 min read

·

Dan Samorodnitsky

Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal

Ovarian cancer

Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie

January 26, 2026

·

2 min read

·

Tristan Manalac

Pros and cons collage. Mixed media thumbs up and thumbs down hand gestures with speech bubbles. Review concept, positive and negative feedback vector illustration.

Immunology and inflammation

Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway

January 23, 2026

·

2 min read

·

Tristan Manalac

Start early or business advantage. Businessman starts running ahead of competitors vector

Pain

Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill

January 22, 2026

·

2 min read

·

Tristan Manalac